[ad_1]
Minneapolis, Minnesota and Cincinnati, Ohio, November 29, 2018 (GLOBE NEWSWIRE) – via NEWMEDIAWIRE – The VigiLanz and Cincinnati Children's Hospital Medical Centers today announced an innovative collaboration on nephrotoxic pediatric kidney injury and VigiLanz's ability to commercialize a solution for acute kidney injury in pediatric patients. Nicknamed NINJA, or nephrotoxic lesion canceled by a just-in-time action, the solution allows for the identification and real-time monitoring of patients at risk of ARI due to exposure to nephrotoxic drugs.
"Acute kidney damage in children is a serious problem that, traditionally, could not be identified in real time, which has affected our ability to identify patients who were most in need of treatment," he said. Dr. Stuart L. Goldstein, MD, Director of the Short-Term Nephrology Care Center and Principal Investigator on NINJA. "By partnering with VigiLanz, Cincinnati Children's is applying its unprecedented research to a commercially available solution that accurately characterizes the epidemiology of ARI in children, reducing IRAs." and improving outcomes for patients. "
Commercially available for hospitals and health systems focused on the mitigation of ARI in children, NINJA automates a tedious manual screening process that includes patient badessment for patients. exposure to 57 nephrotoxic drugs, an imaging contrast dye and recent renal tests. For drugs, manual screening is limited to the last 24 hours, while contrast badessment requires checking the records for the last seven days to see if they have been received by the patient.
By exploiting the NINJA algorithms embedded in the VigiLanz rules, an AKI monitoring dashboard lists all patients who meet the NINJA exposure criteria as well as criteria that place the patient in the risk category. These criteria include drug exposure, serum creatinine data, and AKI history in patients. When patients meet the risk criteria, they are placed on the watch list in real time, where they stay up to 48 hours after the end of the risk.
The platform also features metrics outputs that can be customized for service lines and time periods, while robust reporting tools can track changing conditions over time through graphs and charts. Automated execution. It also allows automatic and customizable data retrieval for all metric items, including inpatient census by location or by-line.
"By broadening the awareness of Cincinnati Children's extensive research, this partnership will help improve AKI's outcomes in pediatrics," said VigiLanz President and CEO, Dr. David Goldsteen, MD, MBA . "These improvements can also be made quickly, because the NINJA dashboard is not just a concept, but rather a concrete solution available to any hospital wishing to limit the AKI badociated with nephrotoxic drugs."
About VigiLanz
Founded in 2001, VigiLanz Corporation (www.vigilanzcorp.com) is a growing, privately-owned provider of predictive intelligence in SaaS healthcare. The company focuses on aggregating EHR transactional workflows and disparate documentation data into healthcare systems to identify real-time clinical problems that prevent or minimize damage, optimize business processes clinical outcomes and support preventive care along the continuum of the health system. VigiLanz supports a growing and growing community of CMOs from hospitals, CMIOs, CIOs, quality teams, infectious disease and control specialists, pharmacists and other clinicians dedicated to time care real to inpatients and outpatients. VigiLanz is shaping the emerging era of real-time healthcare by offering technologies and intelligence services that improve clinical outcomes, patient care and operational efficiencies.
Liz Goar 813-333-2844 [email protected]
Source link
